nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—P-Glycoprotein Inhibitors—Zonisamide—epilepsy syndrome	0.371	1	CiPCiCtD
Crizotinib—TYRO3—epilepsy syndrome	0.111	0.384	CbGaD
Crizotinib—PTK2B—epilepsy syndrome	0.0715	0.248	CbGaD
Crizotinib—TEK—epilepsy syndrome	0.0654	0.226	CbGaD
Crizotinib—SRC—epilepsy syndrome	0.034	0.118	CbGaD
Crizotinib—CYP3A5—Oxcarbazepine—epilepsy syndrome	0.00872	0.0841	CbGbCtD
Crizotinib—ABCB1—epilepsy syndrome	0.00694	0.024	CbGaD
Crizotinib—ABCB1—Levetiracetam—epilepsy syndrome	0.00621	0.0598	CbGbCtD
Crizotinib—CYP3A5—Carbamazepine—epilepsy syndrome	0.00548	0.0528	CbGbCtD
Crizotinib—CYP3A5—Phenytoin—epilepsy syndrome	0.00491	0.0474	CbGbCtD
Crizotinib—CYP3A5—Phenobarbital—epilepsy syndrome	0.00438	0.0422	CbGbCtD
Crizotinib—CYP3A5—Midazolam—epilepsy syndrome	0.00432	0.0416	CbGbCtD
Crizotinib—ABCB1—Clobazam—epilepsy syndrome	0.0043	0.0415	CbGbCtD
Crizotinib—CYP3A5—Diazepam—epilepsy syndrome	0.00415	0.04	CbGbCtD
Crizotinib—ABCB1—Lamotrigine—epilepsy syndrome	0.00414	0.0399	CbGbCtD
Crizotinib—ABCB1—Carbamazepine—epilepsy syndrome	0.00356	0.0344	CbGbCtD
Crizotinib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.0034	0.0328	CbGbCtD
Crizotinib—CYP3A5—Valproic Acid—epilepsy syndrome	0.00327	0.0316	CbGbCtD
Crizotinib—ABCB1—Phenytoin—epilepsy syndrome	0.0032	0.0308	CbGbCtD
Crizotinib—CYP3A4—Trimethadione—epilepsy syndrome	0.00316	0.0305	CbGbCtD
Crizotinib—CYP3A4—Felbamate—epilepsy syndrome	0.00316	0.0305	CbGbCtD
Crizotinib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00297	0.0287	CbGbCtD
Crizotinib—ABCB1—Phenobarbital—epilepsy syndrome	0.00285	0.0275	CbGbCtD
Crizotinib—ABCB1—Midazolam—epilepsy syndrome	0.00281	0.0271	CbGbCtD
Crizotinib—ABCB1—Diazepam—epilepsy syndrome	0.0027	0.026	CbGbCtD
Crizotinib—CYP3A4—Clonazepam—epilepsy syndrome	0.00269	0.0259	CbGbCtD
Crizotinib—CYP3A4—Clobazam—epilepsy syndrome	0.00258	0.0249	CbGbCtD
Crizotinib—CYP3A4—Rufinamide—epilepsy syndrome	0.00219	0.0211	CbGbCtD
Crizotinib—CYP3A4—Carbamazepine—epilepsy syndrome	0.00214	0.0206	CbGbCtD
Crizotinib—CYP3A4—Primidone—epilepsy syndrome	0.00199	0.0192	CbGbCtD
Crizotinib—CYP3A4—Phenytoin—epilepsy syndrome	0.00192	0.0185	CbGbCtD
Crizotinib—CYP3A4—Propofol—epilepsy syndrome	0.00179	0.0172	CbGbCtD
Crizotinib—CYP3A4—Acetazolamide—epilepsy syndrome	0.00171	0.0165	CbGbCtD
Crizotinib—CYP3A4—Phenobarbital—epilepsy syndrome	0.00171	0.0165	CbGbCtD
Crizotinib—CYP3A4—Midazolam—epilepsy syndrome	0.00168	0.0162	CbGbCtD
Crizotinib—CYP3A4—Diazepam—epilepsy syndrome	0.00162	0.0156	CbGbCtD
Crizotinib—CYP3A4—Zonisamide—epilepsy syndrome	0.00158	0.0152	CbGbCtD
Crizotinib—CYP3A4—Valproic Acid—epilepsy syndrome	0.00128	0.0123	CbGbCtD
Crizotinib—CYP3A4—Topiramate—epilepsy syndrome	0.00115	0.0111	CbGbCtD
Crizotinib—AURKA—Pyrimethamine—Lamotrigine—epilepsy syndrome	0.000665	0.484	CbGdCrCtD
Crizotinib—TESK1—Loxapine—Clobazam—epilepsy syndrome	0.000291	0.211	CbGdCrCtD
Crizotinib—TESK1—Loxapine—Diazepam—epilepsy syndrome	0.00027	0.196	CbGdCrCtD
Crizotinib—TNK1—cerebellum—epilepsy syndrome	0.000104	0.00195	CbGeAlD
Crizotinib—MERTK—head—epilepsy syndrome	0.000103	0.00194	CbGeAlD
Crizotinib—TNK2—central nervous system—epilepsy syndrome	0.000103	0.00194	CbGeAlD
Crizotinib—IGF1R—central nervous system—epilepsy syndrome	0.000103	0.00194	CbGeAlD
Crizotinib—BMPR1B—cerebellum—epilepsy syndrome	0.000103	0.00193	CbGeAlD
Crizotinib—RPS6KB1—medulla oblongata—epilepsy syndrome	0.000102	0.00191	CbGeAlD
Crizotinib—CSF1R—forebrain—epilepsy syndrome	0.000102	0.00191	CbGeAlD
Crizotinib—RIPK2—spinal cord—epilepsy syndrome	0.000102	0.00191	CbGeAlD
Crizotinib—AURKA—nervous system—epilepsy syndrome	0.000102	0.00191	CbGeAlD
Crizotinib—LIMK2—head—epilepsy syndrome	0.000101	0.0019	CbGeAlD
Crizotinib—TNK2—cerebellum—epilepsy syndrome	0.000101	0.00189	CbGeAlD
Crizotinib—IGF1R—cerebellum—epilepsy syndrome	0.000101	0.00189	CbGeAlD
Crizotinib—AXL—medulla oblongata—epilepsy syndrome	0.000101	0.00189	CbGeAlD
Crizotinib—CDK7—brain—epilepsy syndrome	0.000101	0.00189	CbGeAlD
Crizotinib—TESK1—nervous system—epilepsy syndrome	0.000101	0.00189	CbGeAlD
Crizotinib—TIE1—central nervous system—epilepsy syndrome	0.0001	0.00188	CbGeAlD
Crizotinib—MAP3K12—head—epilepsy syndrome	0.0001	0.00188	CbGeAlD
Crizotinib—ACVR1—head—epilepsy syndrome	0.0001	0.00188	CbGeAlD
Crizotinib—TAOK2—brain—epilepsy syndrome	0.0001	0.00188	CbGeAlD
Crizotinib—MAP4K2—cerebellum—epilepsy syndrome	9.94e-05	0.00187	CbGeAlD
Crizotinib—STK3—cerebellum—epilepsy syndrome	9.81e-05	0.00184	CbGeAlD
Crizotinib—TIE1—cerebellum—epilepsy syndrome	9.81e-05	0.00184	CbGeAlD
Crizotinib—MERTK—nervous system—epilepsy syndrome	9.8e-05	0.00184	CbGeAlD
Crizotinib—STK35—head—epilepsy syndrome	9.8e-05	0.00184	CbGeAlD
Crizotinib—AURKA—central nervous system—epilepsy syndrome	9.78e-05	0.00184	CbGeAlD
Crizotinib—SLK—medulla oblongata—epilepsy syndrome	9.7e-05	0.00182	CbGeAlD
Crizotinib—TESK1—central nervous system—epilepsy syndrome	9.7e-05	0.00182	CbGeAlD
Crizotinib—PTK2—midbrain—epilepsy syndrome	9.67e-05	0.00182	CbGeAlD
Crizotinib—TBK1—midbrain—epilepsy syndrome	9.67e-05	0.00182	CbGeAlD
Crizotinib—EPHB4—medulla oblongata—epilepsy syndrome	9.63e-05	0.00181	CbGeAlD
Crizotinib—EPHA3—brain—epilepsy syndrome	9.63e-05	0.00181	CbGeAlD
Crizotinib—ACVR1B—brain—epilepsy syndrome	9.63e-05	0.00181	CbGeAlD
Crizotinib—TYK2—midbrain—epilepsy syndrome	9.61e-05	0.0018	CbGeAlD
Crizotinib—LIMK2—nervous system—epilepsy syndrome	9.58e-05	0.0018	CbGeAlD
Crizotinib—JAK2—medulla oblongata—epilepsy syndrome	9.56e-05	0.0018	CbGeAlD
Crizotinib—IRAK1—midbrain—epilepsy syndrome	9.48e-05	0.00178	CbGeAlD
Crizotinib—MAP3K12—nervous system—epilepsy syndrome	9.48e-05	0.00178	CbGeAlD
Crizotinib—ACVR1—nervous system—epilepsy syndrome	9.48e-05	0.00178	CbGeAlD
Crizotinib—TESK1—cerebellum—epilepsy syndrome	9.48e-05	0.00178	CbGeAlD
Crizotinib—PTK2—spinal cord—epilepsy syndrome	9.44e-05	0.00177	CbGeAlD
Crizotinib—TBK1—spinal cord—epilepsy syndrome	9.44e-05	0.00177	CbGeAlD
Crizotinib—MERTK—central nervous system—epilepsy syndrome	9.43e-05	0.00177	CbGeAlD
Crizotinib—BMP2K—head—epilepsy syndrome	9.43e-05	0.00177	CbGeAlD
Crizotinib—TYK2—spinal cord—epilepsy syndrome	9.37e-05	0.00176	CbGeAlD
Crizotinib—CSF1R—telencephalon—epilepsy syndrome	9.36e-05	0.00176	CbGeAlD
Crizotinib—RPS6KB1—midbrain—epilepsy syndrome	9.3e-05	0.00175	CbGeAlD
Crizotinib—STK35—nervous system—epilepsy syndrome	9.29e-05	0.00174	CbGeAlD
Crizotinib—LIMK2—central nervous system—epilepsy syndrome	9.23e-05	0.00173	CbGeAlD
Crizotinib—MERTK—cerebellum—epilepsy syndrome	9.22e-05	0.00173	CbGeAlD
Crizotinib—TEK—medulla oblongata—epilepsy syndrome	9.22e-05	0.00173	CbGeAlD
Crizotinib—MAP3K3—medulla oblongata—epilepsy syndrome	9.22e-05	0.00173	CbGeAlD
Crizotinib—MAP4K5—medulla oblongata—epilepsy syndrome	9.22e-05	0.00173	CbGeAlD
Crizotinib—AXL—midbrain—epilepsy syndrome	9.21e-05	0.00173	CbGeAlD
Crizotinib—EPHA6—brain—epilepsy syndrome	9.19e-05	0.00173	CbGeAlD
Crizotinib—JAK3—brain—epilepsy syndrome	9.19e-05	0.00173	CbGeAlD
Crizotinib—DCLK1—brain—epilepsy syndrome	9.13e-05	0.00171	CbGeAlD
Crizotinib—MAP3K12—central nervous system—epilepsy syndrome	9.13e-05	0.00171	CbGeAlD
Crizotinib—ACVR1—central nervous system—epilepsy syndrome	9.13e-05	0.00171	CbGeAlD
Crizotinib—PTK2B—head—epilepsy syndrome	9.11e-05	0.00171	CbGeAlD
Crizotinib—RPS6KB1—spinal cord—epilepsy syndrome	9.08e-05	0.00171	CbGeAlD
Crizotinib—PLK4—brain—epilepsy syndrome	9.07e-05	0.0017	CbGeAlD
Crizotinib—RIPK2—head—epilepsy syndrome	9.03e-05	0.0017	CbGeAlD
Crizotinib—STK4—brain—epilepsy syndrome	9.02e-05	0.00169	CbGeAlD
Crizotinib—LIMK2—cerebellum—epilepsy syndrome	9.02e-05	0.00169	CbGeAlD
Crizotinib—AXL—spinal cord—epilepsy syndrome	8.99e-05	0.00169	CbGeAlD
Crizotinib—NUAK2—cerebellum—epilepsy syndrome	8.99e-05	0.00169	CbGeAlD
Crizotinib—STK35—central nervous system—epilepsy syndrome	8.94e-05	0.00168	CbGeAlD
Crizotinib—BMP2K—nervous system—epilepsy syndrome	8.94e-05	0.00168	CbGeAlD
Crizotinib—MAP3K12—cerebellum—epilepsy syndrome	8.92e-05	0.00168	CbGeAlD
Crizotinib—FLT3—cerebellum—epilepsy syndrome	8.92e-05	0.00168	CbGeAlD
Crizotinib—ACVR1—cerebellum—epilepsy syndrome	8.92e-05	0.00168	CbGeAlD
Crizotinib—SLK—midbrain—epilepsy syndrome	8.87e-05	0.00167	CbGeAlD
Crizotinib—EPHB6—medulla oblongata—epilepsy syndrome	8.81e-05	0.00165	CbGeAlD
Crizotinib—EPHB4—midbrain—epilepsy syndrome	8.8e-05	0.00165	CbGeAlD
Crizotinib—AURKA—Bortezomib—Lacosamide—epilepsy syndrome	8.78e-05	0.0639	CbGdCrCtD
Crizotinib—STK35—cerebellum—epilepsy syndrome	8.74e-05	0.00164	CbGeAlD
Crizotinib—EPHA4—head—epilepsy syndrome	8.73e-05	0.00164	CbGeAlD
Crizotinib—SLK—spinal cord—epilepsy syndrome	8.65e-05	0.00162	CbGeAlD
Crizotinib—PTK2B—nervous system—epilepsy syndrome	8.63e-05	0.00162	CbGeAlD
Crizotinib—BMP2K—central nervous system—epilepsy syndrome	8.61e-05	0.00162	CbGeAlD
Crizotinib—EPHB4—spinal cord—epilepsy syndrome	8.59e-05	0.00161	CbGeAlD
Crizotinib—MAP3K2—head—epilepsy syndrome	8.56e-05	0.00161	CbGeAlD
Crizotinib—JAK2—spinal cord—epilepsy syndrome	8.53e-05	0.0016	CbGeAlD
Crizotinib—FER—brain—epilepsy syndrome	8.52e-05	0.0016	CbGeAlD
Crizotinib—EPHA5—brain—epilepsy syndrome	8.52e-05	0.0016	CbGeAlD
Crizotinib—ALK—brain—epilepsy syndrome	8.52e-05	0.0016	CbGeAlD
Crizotinib—TYRO3—brain—epilepsy syndrome	8.52e-05	0.0016	CbGeAlD
Crizotinib—ABL2—cerebellum—epilepsy syndrome	8.52e-05	0.0016	CbGeAlD
Crizotinib—YES1—medulla oblongata—epilepsy syndrome	8.51e-05	0.0016	CbGeAlD
Crizotinib—LYN—brain—epilepsy syndrome	8.48e-05	0.00159	CbGeAlD
Crizotinib—TNK1—brain—epilepsy syndrome	8.43e-05	0.00158	CbGeAlD
Crizotinib—MAP3K3—midbrain—epilepsy syndrome	8.42e-05	0.00158	CbGeAlD
Crizotinib—MAP4K5—midbrain—epilepsy syndrome	8.42e-05	0.00158	CbGeAlD
Crizotinib—TEK—midbrain—epilepsy syndrome	8.42e-05	0.00158	CbGeAlD
Crizotinib—BMP2K—cerebellum—epilepsy syndrome	8.41e-05	0.00158	CbGeAlD
Crizotinib—TAOK3—medulla oblongata—epilepsy syndrome	8.4e-05	0.00158	CbGeAlD
Crizotinib—PTK2—head—epilepsy syndrome	8.39e-05	0.00158	CbGeAlD
Crizotinib—TBK1—head—epilepsy syndrome	8.39e-05	0.00158	CbGeAlD
Crizotinib—MAP3K19—brain—epilepsy syndrome	8.35e-05	0.00157	CbGeAlD
Crizotinib—BMPR1B—brain—epilepsy syndrome	8.35e-05	0.00157	CbGeAlD
Crizotinib—MAP4K1—brain—epilepsy syndrome	8.35e-05	0.00157	CbGeAlD
Crizotinib—ABL1—brainstem—epilepsy syndrome	8.33e-05	0.00157	CbGeAlD
Crizotinib—TYK2—head—epilepsy syndrome	8.33e-05	0.00156	CbGeAlD
Crizotinib—PTK2B—central nervous system—epilepsy syndrome	8.31e-05	0.00156	CbGeAlD
Crizotinib—EPHA4—nervous system—epilepsy syndrome	8.28e-05	0.00156	CbGeAlD
Crizotinib—MAP4K5—spinal cord—epilepsy syndrome	8.22e-05	0.00154	CbGeAlD
Crizotinib—MAP3K3—spinal cord—epilepsy syndrome	8.22e-05	0.00154	CbGeAlD
Crizotinib—TEK—spinal cord—epilepsy syndrome	8.22e-05	0.00154	CbGeAlD
Crizotinib—TNK2—brain—epilepsy syndrome	8.19e-05	0.00154	CbGeAlD
Crizotinib—IGF1R—brain—epilepsy syndrome	8.19e-05	0.00154	CbGeAlD
Crizotinib—PTK2B—cerebellum—epilepsy syndrome	8.13e-05	0.00153	CbGeAlD
Crizotinib—MAP3K2—nervous system—epilepsy syndrome	8.12e-05	0.00153	CbGeAlD
Crizotinib—MAP4K2—brain—epilepsy syndrome	8.07e-05	0.00152	CbGeAlD
Crizotinib—RPS6KB1—head—epilepsy syndrome	8.07e-05	0.00152	CbGeAlD
Crizotinib—RIPK2—cerebellum—epilepsy syndrome	8.06e-05	0.00151	CbGeAlD
Crizotinib—EPHB6—midbrain—epilepsy syndrome	8.05e-05	0.00151	CbGeAlD
Crizotinib—FGR—head—epilepsy syndrome	8.02e-05	0.00151	CbGeAlD
Crizotinib—AXL—head—epilepsy syndrome	7.99e-05	0.0015	CbGeAlD
Crizotinib—EPHA4—central nervous system—epilepsy syndrome	7.97e-05	0.0015	CbGeAlD
Crizotinib—STK3—brain—epilepsy syndrome	7.97e-05	0.0015	CbGeAlD
Crizotinib—TIE1—brain—epilepsy syndrome	7.97e-05	0.0015	CbGeAlD
Crizotinib—PTK2—nervous system—epilepsy syndrome	7.95e-05	0.00149	CbGeAlD
Crizotinib—TBK1—nervous system—epilepsy syndrome	7.95e-05	0.00149	CbGeAlD
Crizotinib—TYK2—nervous system—epilepsy syndrome	7.9e-05	0.00148	CbGeAlD
Crizotinib—EPHB6—spinal cord—epilepsy syndrome	7.85e-05	0.00148	CbGeAlD
Crizotinib—MAP3K2—central nervous system—epilepsy syndrome	7.82e-05	0.00147	CbGeAlD
Crizotinib—EPHA4—cerebellum—epilepsy syndrome	7.79e-05	0.00146	CbGeAlD
Crizotinib—YES1—midbrain—epilepsy syndrome	7.78e-05	0.00146	CbGeAlD
Crizotinib—AURKA—brain—epilepsy syndrome	7.76e-05	0.00146	CbGeAlD
Crizotinib—TESK1—brain—epilepsy syndrome	7.7e-05	0.00145	CbGeAlD
Crizotinib—TAOK3—midbrain—epilepsy syndrome	7.68e-05	0.00144	CbGeAlD
Crizotinib—TBK1—central nervous system—epilepsy syndrome	7.65e-05	0.00144	CbGeAlD
Crizotinib—PTK2—central nervous system—epilepsy syndrome	7.65e-05	0.00144	CbGeAlD
Crizotinib—RPS6KB1—nervous system—epilepsy syndrome	7.65e-05	0.00144	CbGeAlD
Crizotinib—MAP3K2—cerebellum—epilepsy syndrome	7.64e-05	0.00144	CbGeAlD
Crizotinib—TYK2—central nervous system—epilepsy syndrome	7.6e-05	0.00143	CbGeAlD
Crizotinib—FGR—nervous system—epilepsy syndrome	7.6e-05	0.00143	CbGeAlD
Crizotinib—YES1—spinal cord—epilepsy syndrome	7.59e-05	0.00143	CbGeAlD
Crizotinib—JAK2—head—epilepsy syndrome	7.58e-05	0.00142	CbGeAlD
Crizotinib—AXL—nervous system—epilepsy syndrome	7.57e-05	0.00142	CbGeAlD
Crizotinib—TAOK3—spinal cord—epilepsy syndrome	7.49e-05	0.00141	CbGeAlD
Crizotinib—MERTK—brain—epilepsy syndrome	7.49e-05	0.00141	CbGeAlD
Crizotinib—EPHA2—head—epilepsy syndrome	7.49e-05	0.00141	CbGeAlD
Crizotinib—TBK1—cerebellum—epilepsy syndrome	7.48e-05	0.00141	CbGeAlD
Crizotinib—PTK2—cerebellum—epilepsy syndrome	7.48e-05	0.00141	CbGeAlD
Crizotinib—TYK2—cerebellum—epilepsy syndrome	7.43e-05	0.0014	CbGeAlD
Crizotinib—ABL1—telencephalon—epilepsy syndrome	7.4e-05	0.00139	CbGeAlD
Crizotinib—RPS6KB1—central nervous system—epilepsy syndrome	7.36e-05	0.00138	CbGeAlD
Crizotinib—CSF1R—medulla oblongata—epilepsy syndrome	7.35e-05	0.00138	CbGeAlD
Crizotinib—IRAK1—cerebellum—epilepsy syndrome	7.34e-05	0.00138	CbGeAlD
Crizotinib—LIMK2—brain—epilepsy syndrome	7.32e-05	0.00138	CbGeAlD
Crizotinib—FGR—central nervous system—epilepsy syndrome	7.32e-05	0.00137	CbGeAlD
Crizotinib—TEK—head—epilepsy syndrome	7.3e-05	0.00137	CbGeAlD
Crizotinib—MAP3K3—head—epilepsy syndrome	7.3e-05	0.00137	CbGeAlD
Crizotinib—MAP4K5—head—epilepsy syndrome	7.3e-05	0.00137	CbGeAlD
Crizotinib—SRC—spinal cord—epilepsy syndrome	7.3e-05	0.00137	CbGeAlD
Crizotinib—NUAK2—brain—epilepsy syndrome	7.3e-05	0.00137	CbGeAlD
Crizotinib—AXL—central nervous system—epilepsy syndrome	7.29e-05	0.00137	CbGeAlD
Crizotinib—MAP3K12—brain—epilepsy syndrome	7.25e-05	0.00136	CbGeAlD
Crizotinib—ACVR1—brain—epilepsy syndrome	7.25e-05	0.00136	CbGeAlD
Crizotinib—RPS6KB1—cerebellum—epilepsy syndrome	7.2e-05	0.00135	CbGeAlD
Crizotinib—JAK2—nervous system—epilepsy syndrome	7.19e-05	0.00135	CbGeAlD
Crizotinib—AXL—cerebellum—epilepsy syndrome	7.13e-05	0.00134	CbGeAlD
Crizotinib—STK35—brain—epilepsy syndrome	7.1e-05	0.00133	CbGeAlD
Crizotinib—EPHA2—nervous system—epilepsy syndrome	7.1e-05	0.00133	CbGeAlD
Crizotinib—EPHB6—head—epilepsy syndrome	6.98e-05	0.00131	CbGeAlD
Crizotinib—TEK—nervous system—epilepsy syndrome	6.93e-05	0.0013	CbGeAlD
Crizotinib—MAP4K5—nervous system—epilepsy syndrome	6.93e-05	0.0013	CbGeAlD
Crizotinib—MAP3K3—nervous system—epilepsy syndrome	6.93e-05	0.0013	CbGeAlD
Crizotinib—ABL2—brain—epilepsy syndrome	6.92e-05	0.0013	CbGeAlD
Crizotinib—JAK2—central nervous system—epilepsy syndrome	6.92e-05	0.0013	CbGeAlD
Crizotinib—SLK—cerebellum—epilepsy syndrome	6.86e-05	0.00129	CbGeAlD
Crizotinib—EPHA2—central nervous system—epilepsy syndrome	6.83e-05	0.00128	CbGeAlD
Crizotinib—BMP2K—brain—epilepsy syndrome	6.83e-05	0.00128	CbGeAlD
Crizotinib—EPHB4—cerebellum—epilepsy syndrome	6.81e-05	0.00128	CbGeAlD
Crizotinib—JAK2—cerebellum—epilepsy syndrome	6.76e-05	0.00127	CbGeAlD
Crizotinib—YES1—head—epilepsy syndrome	6.75e-05	0.00127	CbGeAlD
Crizotinib—CSF1R—midbrain—epilepsy syndrome	6.72e-05	0.00126	CbGeAlD
Crizotinib—STK10—head—epilepsy syndrome	6.68e-05	0.00126	CbGeAlD
Crizotinib—TEK—central nervous system—epilepsy syndrome	6.67e-05	0.00125	CbGeAlD
Crizotinib—MAP4K5—central nervous system—epilepsy syndrome	6.67e-05	0.00125	CbGeAlD
Crizotinib—MAP3K3—central nervous system—epilepsy syndrome	6.67e-05	0.00125	CbGeAlD
Crizotinib—TAOK3—head—epilepsy syndrome	6.66e-05	0.00125	CbGeAlD
Crizotinib—EPHB6—nervous system—epilepsy syndrome	6.62e-05	0.00124	CbGeAlD
Crizotinib—PTK2B—brain—epilepsy syndrome	6.6e-05	0.00124	CbGeAlD
Crizotinib—CSF1R—spinal cord—epilepsy syndrome	6.56e-05	0.00123	CbGeAlD
Crizotinib—RIPK2—brain—epilepsy syndrome	6.55e-05	0.00123	CbGeAlD
Crizotinib—MAP3K3—cerebellum—epilepsy syndrome	6.52e-05	0.00122	CbGeAlD
Crizotinib—MAP4K5—cerebellum—epilepsy syndrome	6.52e-05	0.00122	CbGeAlD
Crizotinib—TEK—cerebellum—epilepsy syndrome	6.52e-05	0.00122	CbGeAlD
Crizotinib—SRC—head—epilepsy syndrome	6.49e-05	0.00122	CbGeAlD
Crizotinib—YES1—nervous system—epilepsy syndrome	6.4e-05	0.0012	CbGeAlD
Crizotinib—EPHB6—central nervous system—epilepsy syndrome	6.37e-05	0.0012	CbGeAlD
Crizotinib—STK10—nervous system—epilepsy syndrome	6.34e-05	0.00119	CbGeAlD
Crizotinib—EPHA4—brain—epilepsy syndrome	6.33e-05	0.00119	CbGeAlD
Crizotinib—TAOK3—nervous system—epilepsy syndrome	6.31e-05	0.00119	CbGeAlD
Crizotinib—EPHB6—cerebellum—epilepsy syndrome	6.23e-05	0.00117	CbGeAlD
Crizotinib—MAP3K2—brain—epilepsy syndrome	6.21e-05	0.00117	CbGeAlD
Crizotinib—YES1—central nervous system—epilepsy syndrome	6.16e-05	0.00116	CbGeAlD
Crizotinib—SRC—nervous system—epilepsy syndrome	6.15e-05	0.00116	CbGeAlD
Crizotinib—STK10—central nervous system—epilepsy syndrome	6.1e-05	0.00115	CbGeAlD
Crizotinib—AURKA—Niclosamide—Clonazepam—epilepsy syndrome	6.09e-05	0.0443	CbGdCrCtD
Crizotinib—TAOK3—central nervous system—epilepsy syndrome	6.08e-05	0.00114	CbGeAlD
Crizotinib—TBK1—brain—epilepsy syndrome	6.08e-05	0.00114	CbGeAlD
Crizotinib—PTK2—brain—epilepsy syndrome	6.08e-05	0.00114	CbGeAlD
Crizotinib—TYK2—brain—epilepsy syndrome	6.04e-05	0.00113	CbGeAlD
Crizotinib—YES1—cerebellum—epilepsy syndrome	6.02e-05	0.00113	CbGeAlD
Crizotinib—STK10—cerebellum—epilepsy syndrome	5.96e-05	0.00112	CbGeAlD
Crizotinib—IRAK1—brain—epilepsy syndrome	5.96e-05	0.00112	CbGeAlD
Crizotinib—TAOK3—cerebellum—epilepsy syndrome	5.94e-05	0.00112	CbGeAlD
Crizotinib—SRC—central nervous system—epilepsy syndrome	5.92e-05	0.00111	CbGeAlD
Crizotinib—RPS6KB1—brain—epilepsy syndrome	5.85e-05	0.0011	CbGeAlD
Crizotinib—CSF1R—head—epilepsy syndrome	5.83e-05	0.00109	CbGeAlD
Crizotinib—ABL1—medulla oblongata—epilepsy syndrome	5.81e-05	0.00109	CbGeAlD
Crizotinib—FGR—brain—epilepsy syndrome	5.81e-05	0.00109	CbGeAlD
Crizotinib—SRC—cerebellum—epilepsy syndrome	5.79e-05	0.00109	CbGeAlD
Crizotinib—AXL—brain—epilepsy syndrome	5.79e-05	0.00109	CbGeAlD
Crizotinib—SLK—brain—epilepsy syndrome	5.57e-05	0.00105	CbGeAlD
Crizotinib—EPHB4—brain—epilepsy syndrome	5.53e-05	0.00104	CbGeAlD
Crizotinib—CSF1R—nervous system—epilepsy syndrome	5.52e-05	0.00104	CbGeAlD
Crizotinib—JAK2—brain—epilepsy syndrome	5.49e-05	0.00103	CbGeAlD
Crizotinib—EPHA2—brain—epilepsy syndrome	5.43e-05	0.00102	CbGeAlD
Crizotinib—CSF1R—central nervous system—epilepsy syndrome	5.32e-05	0.000999	CbGeAlD
Crizotinib—ABL1—midbrain—epilepsy syndrome	5.31e-05	0.000998	CbGeAlD
Crizotinib—MAP3K3—brain—epilepsy syndrome	5.29e-05	0.000994	CbGeAlD
Crizotinib—MAP4K5—brain—epilepsy syndrome	5.29e-05	0.000994	CbGeAlD
Crizotinib—TEK—brain—epilepsy syndrome	5.29e-05	0.000994	CbGeAlD
Crizotinib—CSF1R—cerebellum—epilepsy syndrome	5.2e-05	0.000976	CbGeAlD
Crizotinib—ABL1—spinal cord—epilepsy syndrome	5.18e-05	0.000973	CbGeAlD
Crizotinib—EPHB6—brain—epilepsy syndrome	5.06e-05	0.00095	CbGeAlD
Crizotinib—Gastrointestinal disorder—Phenytoin—epilepsy syndrome	4.93e-05	0.000582	CcSEcCtD
Crizotinib—Fatigue—Phenytoin—epilepsy syndrome	4.92e-05	0.000581	CcSEcCtD
Crizotinib—Constipation—Clonazepam—epilepsy syndrome	4.91e-05	0.00058	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Oxcarbazepine—epilepsy syndrome	4.9e-05	0.000579	CcSEcCtD
Crizotinib—Fatigue—Oxcarbazepine—epilepsy syndrome	4.89e-05	0.000578	CcSEcCtD
Crizotinib—Paraesthesia—Carbamazepine—epilepsy syndrome	4.89e-05	0.000578	CcSEcCtD
Crizotinib—YES1—brain—epilepsy syndrome	4.89e-05	0.000918	CbGeAlD
Crizotinib—Constipation—Phenytoin—epilepsy syndrome	4.88e-05	0.000576	CcSEcCtD
Crizotinib—Asthenia—Levetiracetam—epilepsy syndrome	4.87e-05	0.000576	CcSEcCtD
Crizotinib—Hypoaesthesia—Gabapentin—epilepsy syndrome	4.86e-05	0.000574	CcSEcCtD
Crizotinib—Dyspnoea—Carbamazepine—epilepsy syndrome	4.86e-05	0.000574	CcSEcCtD
Crizotinib—Constipation—Oxcarbazepine—epilepsy syndrome	4.85e-05	0.000573	CcSEcCtD
Crizotinib—STK10—brain—epilepsy syndrome	4.84e-05	0.00091	CbGeAlD
Crizotinib—Vision blurred—Valproic Acid—epilepsy syndrome	4.83e-05	0.000571	CcSEcCtD
Crizotinib—TAOK3—brain—epilepsy syndrome	4.83e-05	0.000907	CbGeAlD
Crizotinib—Urinary tract disorder—Gabapentin—epilepsy syndrome	4.82e-05	0.000569	CcSEcCtD
Crizotinib—Body temperature increased—Felbamate—epilepsy syndrome	4.81e-05	0.000569	CcSEcCtD
Crizotinib—Vomiting—Acetazolamide—epilepsy syndrome	4.81e-05	0.000568	CcSEcCtD
Crizotinib—Diarrhoea—Propofol—epilepsy syndrome	4.81e-05	0.000568	CcSEcCtD
Crizotinib—Oedema peripheral—Gabapentin—epilepsy syndrome	4.81e-05	0.000568	CcSEcCtD
Crizotinib—Neutropenia—Topiramate—epilepsy syndrome	4.8e-05	0.000567	CcSEcCtD
Crizotinib—Mediastinal disorder—Pregabalin—epilepsy syndrome	4.8e-05	0.000567	CcSEcCtD
Crizotinib—Dyspepsia—Carbamazepine—epilepsy syndrome	4.79e-05	0.000566	CcSEcCtD
Crizotinib—Urethral disorder—Gabapentin—epilepsy syndrome	4.78e-05	0.000565	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Topiramate—epilepsy syndrome	4.77e-05	0.000563	CcSEcCtD
Crizotinib—Arrhythmia—Pregabalin—epilepsy syndrome	4.75e-05	0.000562	CcSEcCtD
Crizotinib—Anaemia—Valproic Acid—epilepsy syndrome	4.74e-05	0.00056	CcSEcCtD
Crizotinib—Decreased appetite—Carbamazepine—epilepsy syndrome	4.73e-05	0.000559	CcSEcCtD
Crizotinib—Paraesthesia—Lamotrigine—epilepsy syndrome	4.73e-05	0.000558	CcSEcCtD
Crizotinib—Body temperature increased—Zonisamide—epilepsy syndrome	4.71e-05	0.000557	CcSEcCtD
Crizotinib—Asthenia—Fosphenytoin—epilepsy syndrome	4.7e-05	0.000556	CcSEcCtD
Crizotinib—Visual impairment—Gabapentin—epilepsy syndrome	4.7e-05	0.000556	CcSEcCtD
Crizotinib—SRC—brain—epilepsy syndrome	4.7e-05	0.000883	CbGeAlD
Crizotinib—Gastrointestinal disorder—Carbamazepine—epilepsy syndrome	4.7e-05	0.000555	CcSEcCtD
Crizotinib—Fatigue—Carbamazepine—epilepsy syndrome	4.7e-05	0.000555	CcSEcCtD
Crizotinib—Dyspnoea—Lamotrigine—epilepsy syndrome	4.69e-05	0.000554	CcSEcCtD
Crizotinib—Constipation—Carbamazepine—epilepsy syndrome	4.66e-05	0.00055	CcSEcCtD
Crizotinib—Dizziness—Propofol—epilepsy syndrome	4.65e-05	0.000549	CcSEcCtD
Crizotinib—Diarrhoea—Levetiracetam—epilepsy syndrome	4.65e-05	0.000549	CcSEcCtD
Crizotinib—Weight decreased—Topiramate—epilepsy syndrome	4.64e-05	0.000548	CcSEcCtD
Crizotinib—Dyspepsia—Lamotrigine—epilepsy syndrome	4.63e-05	0.000547	CcSEcCtD
Crizotinib—Malnutrition—Pregabalin—epilepsy syndrome	4.63e-05	0.000547	CcSEcCtD
Crizotinib—ABL1—head—epilepsy syndrome	4.61e-05	0.000865	CbGeAlD
Crizotinib—Pneumonia—Topiramate—epilepsy syndrome	4.6e-05	0.000543	CcSEcCtD
Crizotinib—Leukopenia—Valproic Acid—epilepsy syndrome	4.59e-05	0.000542	CcSEcCtD
Crizotinib—Asthenia—Vigabatrin—epilepsy syndrome	4.58e-05	0.000542	CcSEcCtD
Crizotinib—Decreased appetite—Lamotrigine—epilepsy syndrome	4.58e-05	0.000541	CcSEcCtD
Crizotinib—Infestation NOS—Topiramate—epilepsy syndrome	4.57e-05	0.00054	CcSEcCtD
Crizotinib—Infestation—Topiramate—epilepsy syndrome	4.57e-05	0.00054	CcSEcCtD
Crizotinib—Eye disorder—Gabapentin—epilepsy syndrome	4.56e-05	0.000539	CcSEcCtD
Crizotinib—Dizziness—Midazolam—epilepsy syndrome	4.55e-05	0.000537	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Lamotrigine—epilepsy syndrome	4.54e-05	0.000537	CcSEcCtD
Crizotinib—Body temperature increased—Clonazepam—epilepsy syndrome	4.54e-05	0.000536	CcSEcCtD
Crizotinib—Fatigue—Lamotrigine—epilepsy syndrome	4.54e-05	0.000536	CcSEcCtD
Crizotinib—Dysgeusia—Pregabalin—epilepsy syndrome	4.54e-05	0.000536	CcSEcCtD
Crizotinib—Cardiac disorder—Gabapentin—epilepsy syndrome	4.53e-05	0.000535	CcSEcCtD
Crizotinib—Asthenia—Diazepam—epilepsy syndrome	4.51e-05	0.000533	CcSEcCtD
Crizotinib—Body temperature increased—Phenytoin—epilepsy syndrome	4.51e-05	0.000533	CcSEcCtD
Crizotinib—Constipation—Lamotrigine—epilepsy syndrome	4.5e-05	0.000532	CcSEcCtD
Crizotinib—Nausea—Acetazolamide—epilepsy syndrome	4.5e-05	0.000531	CcSEcCtD
Crizotinib—Dizziness—Levetiracetam—epilepsy syndrome	4.49e-05	0.000531	CcSEcCtD
Crizotinib—Body temperature increased—Oxcarbazepine—epilepsy syndrome	4.49e-05	0.00053	CcSEcCtD
Crizotinib—Diarrhoea—Fosphenytoin—epilepsy syndrome	4.49e-05	0.00053	CcSEcCtD
Crizotinib—Neuropathy peripheral—Topiramate—epilepsy syndrome	4.48e-05	0.00053	CcSEcCtD
Crizotinib—Vomiting—Propofol—epilepsy syndrome	4.47e-05	0.000528	CcSEcCtD
Crizotinib—Rash—Propofol—epilepsy syndrome	4.43e-05	0.000524	CcSEcCtD
Crizotinib—Dermatitis—Propofol—epilepsy syndrome	4.43e-05	0.000523	CcSEcCtD
Crizotinib—Mediastinal disorder—Gabapentin—epilepsy syndrome	4.4e-05	0.00052	CcSEcCtD
Crizotinib—Vomiting—Midazolam—epilepsy syndrome	4.37e-05	0.000517	CcSEcCtD
Crizotinib—Diarrhoea—Vigabatrin—epilepsy syndrome	4.37e-05	0.000516	CcSEcCtD
Crizotinib—Asthenia—Felbamate—epilepsy syndrome	4.37e-05	0.000516	CcSEcCtD
Crizotinib—ABL1—nervous system—epilepsy syndrome	4.37e-05	0.00082	CbGeAlD
Crizotinib—Vision blurred—Pregabalin—epilepsy syndrome	4.37e-05	0.000516	CcSEcCtD
Crizotinib—Rash—Midazolam—epilepsy syndrome	4.34e-05	0.000512	CcSEcCtD
Crizotinib—Dizziness—Fosphenytoin—epilepsy syndrome	4.33e-05	0.000512	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Valproic Acid—epilepsy syndrome	4.33e-05	0.000512	CcSEcCtD
Crizotinib—Dermatitis—Midazolam—epilepsy syndrome	4.33e-05	0.000512	CcSEcCtD
Crizotinib—Vomiting—Levetiracetam—epilepsy syndrome	4.32e-05	0.00051	CcSEcCtD
Crizotinib—Body temperature increased—Carbamazepine—epilepsy syndrome	4.31e-05	0.000509	CcSEcCtD
Crizotinib—Diarrhoea—Diazepam—epilepsy syndrome	4.3e-05	0.000508	CcSEcCtD
Crizotinib—Rash—Levetiracetam—epilepsy syndrome	4.28e-05	0.000506	CcSEcCtD
Crizotinib—Anaemia—Pregabalin—epilepsy syndrome	4.28e-05	0.000506	CcSEcCtD
Crizotinib—Dermatitis—Levetiracetam—epilepsy syndrome	4.28e-05	0.000505	CcSEcCtD
Crizotinib—Asthenia—Zonisamide—epilepsy syndrome	4.28e-05	0.000505	CcSEcCtD
Crizotinib—Malnutrition—Gabapentin—epilepsy syndrome	4.25e-05	0.000502	CcSEcCtD
Crizotinib—Dizziness—Vigabatrin—epilepsy syndrome	4.23e-05	0.000499	CcSEcCtD
Crizotinib—CSF1R—brain—epilepsy syndrome	4.22e-05	0.000793	CbGeAlD
Crizotinib—ABL1—central nervous system—epilepsy syndrome	4.2e-05	0.00079	CbGeAlD
Crizotinib—Oedema—Valproic Acid—epilepsy syndrome	4.18e-05	0.000494	CcSEcCtD
Crizotinib—Bradycardia—Topiramate—epilepsy syndrome	4.18e-05	0.000494	CcSEcCtD
Crizotinib—Nausea—Propofol—epilepsy syndrome	4.18e-05	0.000493	CcSEcCtD
Crizotinib—Vomiting—Fosphenytoin—epilepsy syndrome	4.17e-05	0.000492	CcSEcCtD
Crizotinib—Diarrhoea—Felbamate—epilepsy syndrome	4.17e-05	0.000492	CcSEcCtD
Crizotinib—Body temperature increased—Lamotrigine—epilepsy syndrome	4.16e-05	0.000492	CcSEcCtD
Crizotinib—Dysgeusia—Gabapentin—epilepsy syndrome	4.16e-05	0.000491	CcSEcCtD
Crizotinib—Dizziness—Diazepam—epilepsy syndrome	4.16e-05	0.000491	CcSEcCtD
Crizotinib—Infection—Valproic Acid—epilepsy syndrome	4.16e-05	0.000491	CcSEcCtD
Crizotinib—Syncope—Pregabalin—epilepsy syndrome	4.15e-05	0.000491	CcSEcCtD
Crizotinib—Leukopenia—Pregabalin—epilepsy syndrome	4.15e-05	0.00049	CcSEcCtD
Crizotinib—Rash—Fosphenytoin—epilepsy syndrome	4.13e-05	0.000488	CcSEcCtD
Crizotinib—Dermatitis—Fosphenytoin—epilepsy syndrome	4.13e-05	0.000488	CcSEcCtD
Crizotinib—Asthenia—Clonazepam—epilepsy syndrome	4.12e-05	0.000487	CcSEcCtD
Crizotinib—ABL1—cerebellum—epilepsy syndrome	4.11e-05	0.000772	CbGeAlD
Crizotinib—Nervous system disorder—Valproic Acid—epilepsy syndrome	4.1e-05	0.000485	CcSEcCtD
Crizotinib—Asthenia—Phenytoin—epilepsy syndrome	4.09e-05	0.000484	CcSEcCtD
Crizotinib—Nausea—Midazolam—epilepsy syndrome	4.09e-05	0.000483	CcSEcCtD
Crizotinib—Hypoaesthesia—Topiramate—epilepsy syndrome	4.09e-05	0.000483	CcSEcCtD
Crizotinib—Diarrhoea—Zonisamide—epilepsy syndrome	4.08e-05	0.000482	CcSEcCtD
Crizotinib—Loss of consciousness—Pregabalin—epilepsy syndrome	4.07e-05	0.000481	CcSEcCtD
Crizotinib—Asthenia—Oxcarbazepine—epilepsy syndrome	4.07e-05	0.000481	CcSEcCtD
Crizotinib—Vomiting—Vigabatrin—epilepsy syndrome	4.06e-05	0.00048	CcSEcCtD
Crizotinib—Skin disorder—Valproic Acid—epilepsy syndrome	4.06e-05	0.00048	CcSEcCtD
Crizotinib—Urinary tract disorder—Topiramate—epilepsy syndrome	4.05e-05	0.000479	CcSEcCtD
Crizotinib—Oedema peripheral—Topiramate—epilepsy syndrome	4.04e-05	0.000478	CcSEcCtD
Crizotinib—Nausea—Levetiracetam—epilepsy syndrome	4.03e-05	0.000477	CcSEcCtD
Crizotinib—Rash—Vigabatrin—epilepsy syndrome	4.03e-05	0.000476	CcSEcCtD
Crizotinib—Dizziness—Felbamate—epilepsy syndrome	4.03e-05	0.000476	CcSEcCtD
Crizotinib—Dermatitis—Vigabatrin—epilepsy syndrome	4.03e-05	0.000476	CcSEcCtD
Crizotinib—Urethral disorder—Topiramate—epilepsy syndrome	4.02e-05	0.000475	CcSEcCtD
Crizotinib—Vision blurred—Gabapentin—epilepsy syndrome	4e-05	0.000473	CcSEcCtD
Crizotinib—Vomiting—Diazepam—epilepsy syndrome	4e-05	0.000473	CcSEcCtD
Crizotinib—Rash—Diazepam—epilepsy syndrome	3.97e-05	0.000469	CcSEcCtD
Crizotinib—Dermatitis—Diazepam—epilepsy syndrome	3.96e-05	0.000468	CcSEcCtD
Crizotinib—Visual impairment—Topiramate—epilepsy syndrome	3.96e-05	0.000467	CcSEcCtD
Crizotinib—Dizziness—Zonisamide—epilepsy syndrome	3.94e-05	0.000466	CcSEcCtD
Crizotinib—Diarrhoea—Clonazepam—epilepsy syndrome	3.93e-05	0.000464	CcSEcCtD
Crizotinib—Anaemia—Gabapentin—epilepsy syndrome	3.93e-05	0.000464	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	3.92e-05	0.000463	CcSEcCtD
Crizotinib—Asthenia—Carbamazepine—epilepsy syndrome	3.91e-05	0.000462	CcSEcCtD
Crizotinib—Diarrhoea—Phenytoin—epilepsy syndrome	3.9e-05	0.000461	CcSEcCtD
Crizotinib—Nausea—Fosphenytoin—epilepsy syndrome	3.89e-05	0.00046	CcSEcCtD
Crizotinib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	3.88e-05	0.000459	CcSEcCtD
Crizotinib—Vomiting—Felbamate—epilepsy syndrome	3.87e-05	0.000457	CcSEcCtD
Crizotinib—Rash—Felbamate—epilepsy syndrome	3.84e-05	0.000454	CcSEcCtD
Crizotinib—Eye disorder—Topiramate—epilepsy syndrome	3.84e-05	0.000453	CcSEcCtD
Crizotinib—Dermatitis—Felbamate—epilepsy syndrome	3.84e-05	0.000453	CcSEcCtD
Crizotinib—Cardiac disorder—Topiramate—epilepsy syndrome	3.81e-05	0.00045	CcSEcCtD
Crizotinib—Syncope—Gabapentin—epilepsy syndrome	3.81e-05	0.00045	CcSEcCtD
Crizotinib—Leukopenia—Gabapentin—epilepsy syndrome	3.8e-05	0.000449	CcSEcCtD
Crizotinib—Dizziness—Clonazepam—epilepsy syndrome	3.8e-05	0.000449	CcSEcCtD
Crizotinib—Nausea—Vigabatrin—epilepsy syndrome	3.8e-05	0.000448	CcSEcCtD
Crizotinib—Vomiting—Zonisamide—epilepsy syndrome	3.79e-05	0.000448	CcSEcCtD
Crizotinib—Oedema—Pregabalin—epilepsy syndrome	3.78e-05	0.000447	CcSEcCtD
Crizotinib—Asthenia—Lamotrigine—epilepsy syndrome	3.78e-05	0.000446	CcSEcCtD
Crizotinib—Dizziness—Phenytoin—epilepsy syndrome	3.77e-05	0.000446	CcSEcCtD
Crizotinib—Rash—Zonisamide—epilepsy syndrome	3.76e-05	0.000444	CcSEcCtD
Crizotinib—Infection—Pregabalin—epilepsy syndrome	3.76e-05	0.000444	CcSEcCtD
Crizotinib—Paraesthesia—Valproic Acid—epilepsy syndrome	3.76e-05	0.000444	CcSEcCtD
Crizotinib—Dermatitis—Zonisamide—epilepsy syndrome	3.75e-05	0.000444	CcSEcCtD
Crizotinib—Dizziness—Oxcarbazepine—epilepsy syndrome	3.75e-05	0.000443	CcSEcCtD
Crizotinib—Nausea—Diazepam—epilepsy syndrome	3.74e-05	0.000441	CcSEcCtD
Crizotinib—Loss of consciousness—Gabapentin—epilepsy syndrome	3.73e-05	0.000441	CcSEcCtD
Crizotinib—Dyspnoea—Valproic Acid—epilepsy syndrome	3.73e-05	0.00044	CcSEcCtD
Crizotinib—Diarrhoea—Carbamazepine—epilepsy syndrome	3.73e-05	0.00044	CcSEcCtD
Crizotinib—Shock—Pregabalin—epilepsy syndrome	3.72e-05	0.000439	CcSEcCtD
Crizotinib—Nervous system disorder—Pregabalin—epilepsy syndrome	3.71e-05	0.000438	CcSEcCtD
Crizotinib—Mediastinal disorder—Topiramate—epilepsy syndrome	3.7e-05	0.000437	CcSEcCtD
Crizotinib—Dyspepsia—Valproic Acid—epilepsy syndrome	3.68e-05	0.000435	CcSEcCtD
Crizotinib—Skin disorder—Pregabalin—epilepsy syndrome	3.67e-05	0.000434	CcSEcCtD
Crizotinib—Vomiting—Clonazepam—epilepsy syndrome	3.65e-05	0.000431	CcSEcCtD
Crizotinib—Decreased appetite—Valproic Acid—epilepsy syndrome	3.64e-05	0.00043	CcSEcCtD
Crizotinib—Vomiting—Phenytoin—epilepsy syndrome	3.63e-05	0.000429	CcSEcCtD
Crizotinib—Rash—Clonazepam—epilepsy syndrome	3.62e-05	0.000428	CcSEcCtD
Crizotinib—Dermatitis—Clonazepam—epilepsy syndrome	3.62e-05	0.000427	CcSEcCtD
Crizotinib—Nausea—Felbamate—epilepsy syndrome	3.62e-05	0.000427	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	3.61e-05	0.000427	CcSEcCtD
Crizotinib—Vomiting—Oxcarbazepine—epilepsy syndrome	3.61e-05	0.000426	CcSEcCtD
Crizotinib—Fatigue—Valproic Acid—epilepsy syndrome	3.61e-05	0.000426	CcSEcCtD
Crizotinib—Dizziness—Carbamazepine—epilepsy syndrome	3.6e-05	0.000425	CcSEcCtD
Crizotinib—Diarrhoea—Lamotrigine—epilepsy syndrome	3.6e-05	0.000425	CcSEcCtD
Crizotinib—Rash—Phenytoin—epilepsy syndrome	3.6e-05	0.000425	CcSEcCtD
Crizotinib—Dermatitis—Phenytoin—epilepsy syndrome	3.59e-05	0.000425	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	3.59e-05	0.000424	CcSEcCtD
Crizotinib—Rash—Oxcarbazepine—epilepsy syndrome	3.58e-05	0.000423	CcSEcCtD
Crizotinib—Constipation—Valproic Acid—epilepsy syndrome	3.58e-05	0.000423	CcSEcCtD
Crizotinib—Dermatitis—Oxcarbazepine—epilepsy syndrome	3.57e-05	0.000422	CcSEcCtD
Crizotinib—Malnutrition—Topiramate—epilepsy syndrome	3.57e-05	0.000422	CcSEcCtD
Crizotinib—Nausea—Zonisamide—epilepsy syndrome	3.54e-05	0.000418	CcSEcCtD
Crizotinib—Dysgeusia—Topiramate—epilepsy syndrome	3.5e-05	0.000413	CcSEcCtD
Crizotinib—Dizziness—Lamotrigine—epilepsy syndrome	3.48e-05	0.000411	CcSEcCtD
Crizotinib—Oedema—Gabapentin—epilepsy syndrome	3.47e-05	0.00041	CcSEcCtD
Crizotinib—Vomiting—Carbamazepine—epilepsy syndrome	3.46e-05	0.000409	CcSEcCtD
Crizotinib—Infection—Gabapentin—epilepsy syndrome	3.44e-05	0.000407	CcSEcCtD
Crizotinib—Rash—Carbamazepine—epilepsy syndrome	3.43e-05	0.000406	CcSEcCtD
Crizotinib—Dermatitis—Carbamazepine—epilepsy syndrome	3.43e-05	0.000405	CcSEcCtD
Crizotinib—Nausea—Clonazepam—epilepsy syndrome	3.41e-05	0.000403	CcSEcCtD
Crizotinib—Shock—Gabapentin—epilepsy syndrome	3.41e-05	0.000403	CcSEcCtD
Crizotinib—Nervous system disorder—Gabapentin—epilepsy syndrome	3.4e-05	0.000402	CcSEcCtD
Crizotinib—Paraesthesia—Pregabalin—epilepsy syndrome	3.4e-05	0.000401	CcSEcCtD
Crizotinib—Nausea—Phenytoin—epilepsy syndrome	3.39e-05	0.0004	CcSEcCtD
Crizotinib—Dyspnoea—Pregabalin—epilepsy syndrome	3.37e-05	0.000398	CcSEcCtD
Crizotinib—Nausea—Oxcarbazepine—epilepsy syndrome	3.37e-05	0.000398	CcSEcCtD
Crizotinib—Vision blurred—Topiramate—epilepsy syndrome	3.37e-05	0.000398	CcSEcCtD
Crizotinib—Skin disorder—Gabapentin—epilepsy syndrome	3.37e-05	0.000398	CcSEcCtD
Crizotinib—Vomiting—Lamotrigine—epilepsy syndrome	3.35e-05	0.000395	CcSEcCtD
Crizotinib—ABL1—brain—epilepsy syndrome	3.34e-05	0.000627	CbGeAlD
Crizotinib—Rash—Lamotrigine—epilepsy syndrome	3.32e-05	0.000392	CcSEcCtD
Crizotinib—Dermatitis—Lamotrigine—epilepsy syndrome	3.32e-05	0.000392	CcSEcCtD
Crizotinib—Body temperature increased—Valproic Acid—epilepsy syndrome	3.31e-05	0.000391	CcSEcCtD
Crizotinib—Anaemia—Topiramate—epilepsy syndrome	3.3e-05	0.00039	CcSEcCtD
Crizotinib—Decreased appetite—Pregabalin—epilepsy syndrome	3.29e-05	0.000388	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	3.26e-05	0.000386	CcSEcCtD
Crizotinib—Fatigue—Pregabalin—epilepsy syndrome	3.26e-05	0.000385	CcSEcCtD
Crizotinib—Nausea—Carbamazepine—epilepsy syndrome	3.23e-05	0.000382	CcSEcCtD
Crizotinib—Constipation—Pregabalin—epilepsy syndrome	3.23e-05	0.000382	CcSEcCtD
Crizotinib—Syncope—Topiramate—epilepsy syndrome	3.21e-05	0.000379	CcSEcCtD
Crizotinib—Leukopenia—Topiramate—epilepsy syndrome	3.2e-05	0.000378	CcSEcCtD
Crizotinib—Loss of consciousness—Topiramate—epilepsy syndrome	3.14e-05	0.000371	CcSEcCtD
Crizotinib—Nausea—Lamotrigine—epilepsy syndrome	3.13e-05	0.000369	CcSEcCtD
Crizotinib—Paraesthesia—Gabapentin—epilepsy syndrome	3.11e-05	0.000368	CcSEcCtD
Crizotinib—Dyspnoea—Gabapentin—epilepsy syndrome	3.09e-05	0.000365	CcSEcCtD
Crizotinib—Dyspepsia—Gabapentin—epilepsy syndrome	3.05e-05	0.000361	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	3.02e-05	0.000357	CcSEcCtD
Crizotinib—Decreased appetite—Gabapentin—epilepsy syndrome	3.01e-05	0.000356	CcSEcCtD
Crizotinib—Asthenia—Valproic Acid—epilepsy syndrome	3e-05	0.000354	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	2.99e-05	0.000354	CcSEcCtD
Crizotinib—Fatigue—Gabapentin—epilepsy syndrome	2.99e-05	0.000353	CcSEcCtD
Crizotinib—Body temperature increased—Pregabalin—epilepsy syndrome	2.99e-05	0.000353	CcSEcCtD
Crizotinib—Constipation—Gabapentin—epilepsy syndrome	2.96e-05	0.00035	CcSEcCtD
Crizotinib—Oedema—Topiramate—epilepsy syndrome	2.92e-05	0.000345	CcSEcCtD
Crizotinib—Infection—Topiramate—epilepsy syndrome	2.9e-05	0.000342	CcSEcCtD
Crizotinib—Shock—Topiramate—epilepsy syndrome	2.87e-05	0.000339	CcSEcCtD
Crizotinib—Diarrhoea—Valproic Acid—epilepsy syndrome	2.86e-05	0.000338	CcSEcCtD
Crizotinib—Nervous system disorder—Topiramate—epilepsy syndrome	2.86e-05	0.000338	CcSEcCtD
Crizotinib—Skin disorder—Topiramate—epilepsy syndrome	2.83e-05	0.000335	CcSEcCtD
Crizotinib—Dizziness—Valproic Acid—epilepsy syndrome	2.77e-05	0.000327	CcSEcCtD
Crizotinib—Body temperature increased—Gabapentin—epilepsy syndrome	2.74e-05	0.000324	CcSEcCtD
Crizotinib—Asthenia—Pregabalin—epilepsy syndrome	2.71e-05	0.00032	CcSEcCtD
Crizotinib—Vomiting—Valproic Acid—epilepsy syndrome	2.66e-05	0.000314	CcSEcCtD
Crizotinib—Rash—Valproic Acid—epilepsy syndrome	2.64e-05	0.000312	CcSEcCtD
Crizotinib—Dermatitis—Valproic Acid—epilepsy syndrome	2.63e-05	0.000311	CcSEcCtD
Crizotinib—Paraesthesia—Topiramate—epilepsy syndrome	2.62e-05	0.000309	CcSEcCtD
Crizotinib—Dyspnoea—Topiramate—epilepsy syndrome	2.6e-05	0.000307	CcSEcCtD
Crizotinib—Diarrhoea—Pregabalin—epilepsy syndrome	2.59e-05	0.000306	CcSEcCtD
Crizotinib—Dyspepsia—Topiramate—epilepsy syndrome	2.57e-05	0.000303	CcSEcCtD
Crizotinib—Decreased appetite—Topiramate—epilepsy syndrome	2.54e-05	0.0003	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.52e-05	0.000298	CcSEcCtD
Crizotinib—Fatigue—Topiramate—epilepsy syndrome	2.51e-05	0.000297	CcSEcCtD
Crizotinib—ABCB1—forebrain—epilepsy syndrome	2.5e-05	0.00047	CbGeAlD
Crizotinib—Dizziness—Pregabalin—epilepsy syndrome	2.5e-05	0.000295	CcSEcCtD
Crizotinib—Constipation—Topiramate—epilepsy syndrome	2.49e-05	0.000295	CcSEcCtD
Crizotinib—Asthenia—Gabapentin—epilepsy syndrome	2.49e-05	0.000294	CcSEcCtD
Crizotinib—Nausea—Valproic Acid—epilepsy syndrome	2.48e-05	0.000293	CcSEcCtD
Crizotinib—Vomiting—Pregabalin—epilepsy syndrome	2.4e-05	0.000284	CcSEcCtD
Crizotinib—Rash—Pregabalin—epilepsy syndrome	2.38e-05	0.000282	CcSEcCtD
Crizotinib—Dermatitis—Pregabalin—epilepsy syndrome	2.38e-05	0.000281	CcSEcCtD
Crizotinib—Diarrhoea—Gabapentin—epilepsy syndrome	2.37e-05	0.00028	CcSEcCtD
Crizotinib—Body temperature increased—Topiramate—epilepsy syndrome	2.31e-05	0.000272	CcSEcCtD
Crizotinib—ABCB1—telencephalon—epilepsy syndrome	2.3e-05	0.000432	CbGeAlD
Crizotinib—Dizziness—Gabapentin—epilepsy syndrome	2.29e-05	0.000271	CcSEcCtD
Crizotinib—Nausea—Pregabalin—epilepsy syndrome	2.25e-05	0.000265	CcSEcCtD
Crizotinib—Vomiting—Gabapentin—epilepsy syndrome	2.2e-05	0.00026	CcSEcCtD
Crizotinib—Rash—Gabapentin—epilepsy syndrome	2.19e-05	0.000258	CcSEcCtD
Crizotinib—Dermatitis—Gabapentin—epilepsy syndrome	2.18e-05	0.000258	CcSEcCtD
Crizotinib—Asthenia—Topiramate—epilepsy syndrome	2.09e-05	0.000247	CcSEcCtD
Crizotinib—Nausea—Gabapentin—epilepsy syndrome	2.06e-05	0.000243	CcSEcCtD
Crizotinib—Diarrhoea—Topiramate—epilepsy syndrome	2e-05	0.000236	CcSEcCtD
Crizotinib—Dizziness—Topiramate—epilepsy syndrome	1.93e-05	0.000228	CcSEcCtD
Crizotinib—CYP3A4—nervous system—epilepsy syndrome	1.92e-05	0.00036	CbGeAlD
Crizotinib—Vomiting—Topiramate—epilepsy syndrome	1.85e-05	0.000219	CcSEcCtD
Crizotinib—CYP3A4—central nervous system—epilepsy syndrome	1.85e-05	0.000347	CbGeAlD
Crizotinib—Rash—Topiramate—epilepsy syndrome	1.84e-05	0.000217	CcSEcCtD
Crizotinib—Dermatitis—Topiramate—epilepsy syndrome	1.84e-05	0.000217	CcSEcCtD
Crizotinib—ABCB1—medulla oblongata—epilepsy syndrome	1.81e-05	0.000339	CbGeAlD
Crizotinib—Nausea—Topiramate—epilepsy syndrome	1.73e-05	0.000205	CcSEcCtD
Crizotinib—ABCB1—midbrain—epilepsy syndrome	1.65e-05	0.00031	CbGeAlD
Crizotinib—ABCB1—spinal cord—epilepsy syndrome	1.61e-05	0.000303	CbGeAlD
Crizotinib—ABCB1—head—epilepsy syndrome	1.43e-05	0.000269	CbGeAlD
Crizotinib—ABCB1—nervous system—epilepsy syndrome	1.36e-05	0.000255	CbGeAlD
Crizotinib—ABCB1—central nervous system—epilepsy syndrome	1.31e-05	0.000246	CbGeAlD
Crizotinib—ABCB1—cerebellum—epilepsy syndrome	1.28e-05	0.00024	CbGeAlD
Crizotinib—ABCB1—brain—epilepsy syndrome	1.04e-05	0.000195	CbGeAlD
Crizotinib—SRC—Signaling Pathways—SOCS3—epilepsy syndrome	3.4e-07	3.5e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—H2AFX—epilepsy syndrome	3.4e-07	3.5e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MEF2C—epilepsy syndrome	3.4e-07	3.49e-06	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—AKT1—epilepsy syndrome	3.4e-07	3.49e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CDC42—epilepsy syndrome	3.4e-07	3.49e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—FGF2—epilepsy syndrome	3.39e-07	3.48e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GLUL—epilepsy syndrome	3.39e-07	3.48e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—FOS—epilepsy syndrome	3.38e-07	3.48e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS2—epilepsy syndrome	3.38e-07	3.48e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—FGF2—epilepsy syndrome	3.38e-07	3.47e-06	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—AKT1—epilepsy syndrome	3.37e-07	3.47e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—SRC—epilepsy syndrome	3.37e-07	3.46e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—RELA—epilepsy syndrome	3.36e-07	3.46e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TSC2—epilepsy syndrome	3.35e-07	3.45e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—JUN—epilepsy syndrome	3.35e-07	3.44e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AGT—epilepsy syndrome	3.35e-07	3.44e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—MMP9—epilepsy syndrome	3.34e-07	3.43e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—JUN—epilepsy syndrome	3.33e-07	3.43e-06	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	3.33e-07	3.43e-06	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—AKT1—epilepsy syndrome	3.33e-07	3.43e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	3.32e-07	3.42e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—SRC—epilepsy syndrome	3.32e-07	3.41e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—RELA—epilepsy syndrome	3.31e-07	3.41e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—CASP8—epilepsy syndrome	3.31e-07	3.4e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PRKCB—epilepsy syndrome	3.31e-07	3.4e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MTOR—epilepsy syndrome	3.3e-07	3.39e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6ST—epilepsy syndrome	3.29e-07	3.39e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AVP—epilepsy syndrome	3.29e-07	3.38e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—FGF2—epilepsy syndrome	3.29e-07	3.38e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—YWHAZ—epilepsy syndrome	3.28e-07	3.38e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—APOE—epilepsy syndrome	3.28e-07	3.37e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—epilepsy syndrome	3.28e-07	3.37e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MTOR—epilepsy syndrome	3.25e-07	3.34e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NGF—epilepsy syndrome	3.25e-07	3.34e-06	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—AKT1—epilepsy syndrome	3.25e-07	3.34e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MTOR—epilepsy syndrome	3.24e-07	3.33e-06	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—AKT1—epilepsy syndrome	3.24e-07	3.33e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL1B—epilepsy syndrome	3.23e-07	3.33e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—epilepsy syndrome	3.23e-07	3.32e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KDR—epilepsy syndrome	3.21e-07	3.3e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—epilepsy syndrome	3.21e-07	3.3e-06	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—AKT1—epilepsy syndrome	3.21e-07	3.3e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—BCL2—epilepsy syndrome	3.21e-07	3.3e-06	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—AKT1—epilepsy syndrome	3.19e-07	3.28e-06	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—AKT1—epilepsy syndrome	3.19e-07	3.28e-06	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—AKT1—epilepsy syndrome	3.18e-07	3.27e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—SRC—epilepsy syndrome	3.18e-07	3.27e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCR5—epilepsy syndrome	3.16e-07	3.25e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	3.16e-07	3.25e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—RELA—epilepsy syndrome	3.14e-07	3.23e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—JUN—epilepsy syndrome	3.13e-07	3.22e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—RELA—epilepsy syndrome	3.13e-07	3.22e-06	CbGpPWpGaD
Crizotinib—CDK7—Disease—AKT1—epilepsy syndrome	3.13e-07	3.22e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—FGF2—epilepsy syndrome	3.12e-07	3.2e-06	CbGpPWpGaD
Crizotinib—BLK—Immune System—AKT1—epilepsy syndrome	3.11e-07	3.2e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—HMOX1—epilepsy syndrome	3.11e-07	3.2e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HES1—epilepsy syndrome	3.11e-07	3.2e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	3.11e-07	3.2e-06	CbGpPWpGaD
Crizotinib—FGR—Immune System—AKT1—epilepsy syndrome	3.1e-07	3.19e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PRKCB—epilepsy syndrome	3.09e-07	3.18e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—epilepsy syndrome	3.09e-07	3.18e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR2A—epilepsy syndrome	3.09e-07	3.18e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MTOR—epilepsy syndrome	3.08e-07	3.17e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6ST—epilepsy syndrome	3.08e-07	3.17e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—SRC—epilepsy syndrome	3.08e-07	3.17e-06	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—AKT1—epilepsy syndrome	3.08e-07	3.17e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—MTOR—epilepsy syndrome	3.07e-07	3.16e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CAT—epilepsy syndrome	3.07e-07	3.16e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—RELA—epilepsy syndrome	3.05e-07	3.14e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CASP3—epilepsy syndrome	3.03e-07	3.12e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FYN—epilepsy syndrome	3.02e-07	3.11e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	3.02e-07	3.1e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—H2AFX—epilepsy syndrome	3.01e-07	3.1e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—POMC—epilepsy syndrome	3.01e-07	3.1e-06	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	3.01e-07	3.09e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MEF2C—epilepsy syndrome	3.01e-07	3.09e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—SRC—epilepsy syndrome	3e-07	3.09e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	3e-07	3.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—AKT1—epilepsy syndrome	3e-07	3.08e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—epilepsy syndrome	3e-07	3.08e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MTOR—epilepsy syndrome	2.99e-07	3.08e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—BCHE—epilepsy syndrome	2.99e-07	3.08e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—SRC—epilepsy syndrome	2.99e-07	3.08e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CASP3—epilepsy syndrome	2.99e-07	3.07e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—FGF2—epilepsy syndrome	2.99e-07	3.07e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ABCB1—epilepsy syndrome	2.99e-07	3.07e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCL2—epilepsy syndrome	2.95e-07	3.03e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—JUN—epilepsy syndrome	2.94e-07	3.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TSC2—epilepsy syndrome	2.94e-07	3.02e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AGT—epilepsy syndrome	2.93e-07	3.02e-06	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—AKT1—epilepsy syndrome	2.92e-07	3e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—YWHAZ—epilepsy syndrome	2.91e-07	2.99e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—JUN—epilepsy syndrome	2.9e-07	2.99e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NGF—epilepsy syndrome	2.87e-07	2.96e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APOE—epilepsy syndrome	2.87e-07	2.95e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MMP9—epilepsy syndrome	2.87e-07	2.95e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	2.85e-07	2.93e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—BCL2—epilepsy syndrome	2.84e-07	2.92e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MTOR—epilepsy syndrome	2.84e-07	2.92e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CASP3—epilepsy syndrome	2.84e-07	2.92e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL1B—epilepsy syndrome	2.83e-07	2.91e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MMP9—epilepsy syndrome	2.83e-07	2.91e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PLCB1—epilepsy syndrome	2.82e-07	2.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—POMC—epilepsy syndrome	2.82e-07	2.9e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KDR—epilepsy syndrome	2.81e-07	2.89e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—TH—epilepsy syndrome	2.81e-07	2.89e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—SRC—epilepsy syndrome	2.81e-07	2.89e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—epilepsy syndrome	2.81e-07	2.89e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCR5—epilepsy syndrome	2.8e-07	2.87e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—GPX1—epilepsy syndrome	2.78e-07	2.85e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—RELA—epilepsy syndrome	2.77e-07	2.85e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—FGF2—epilepsy syndrome	2.76e-07	2.84e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCL2—epilepsy syndrome	2.76e-07	2.84e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—JUN—epilepsy syndrome	2.75e-07	2.83e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CASP3—epilepsy syndrome	2.75e-07	2.83e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—JUN—epilepsy syndrome	2.75e-07	2.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR2A—epilepsy syndrome	2.74e-07	2.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	2.73e-07	2.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	2.73e-07	2.81e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—MTOR—epilepsy syndrome	2.72e-07	2.8e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PRKCB—epilepsy syndrome	2.71e-07	2.79e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6ST—epilepsy syndrome	2.7e-07	2.78e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MMP9—epilepsy syndrome	2.68e-07	2.76e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—JUN—epilepsy syndrome	2.67e-07	2.75e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—FGF2—epilepsy syndrome	2.66e-07	2.74e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—SRC—epilepsy syndrome	2.64e-07	2.72e-06	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—AKT1—epilepsy syndrome	2.63e-07	2.71e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—epilepsy syndrome	2.63e-07	2.7e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—SRC—epilepsy syndrome	2.61e-07	2.68e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—epilepsy syndrome	2.6e-07	2.68e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TSC2—epilepsy syndrome	2.6e-07	2.67e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AGT—epilepsy syndrome	2.6e-07	2.67e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—SRC—epilepsy syndrome	2.6e-07	2.67e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—epilepsy syndrome	2.58e-07	2.66e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—epilepsy syndrome	2.57e-07	2.65e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APOE—epilepsy syndrome	2.54e-07	2.62e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—epilepsy syndrome	2.54e-07	2.61e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—epilepsy syndrome	2.54e-07	2.61e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—epilepsy syndrome	2.52e-07	2.59e-06	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—epilepsy syndrome	2.52e-07	2.59e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MTOR—epilepsy syndrome	2.51e-07	2.58e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—epilepsy syndrome	2.51e-07	2.58e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—epilepsy syndrome	2.5e-07	2.57e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KDR—epilepsy syndrome	2.49e-07	2.56e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGF2—epilepsy syndrome	2.49e-07	2.56e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—epilepsy syndrome	2.49e-07	2.56e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RELA—epilepsy syndrome	2.47e-07	2.54e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—SRC—epilepsy syndrome	2.47e-07	2.54e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—POMC—epilepsy syndrome	2.47e-07	2.54e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—SRC—epilepsy syndrome	2.46e-07	2.53e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AGT—epilepsy syndrome	2.43e-07	2.5e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—JUN—epilepsy syndrome	2.43e-07	2.5e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MTOR—epilepsy syndrome	2.42e-07	2.49e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCL2—epilepsy syndrome	2.41e-07	2.48e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—epilepsy syndrome	2.41e-07	2.47e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—SRC—epilepsy syndrome	2.4e-07	2.47e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PRKCB—epilepsy syndrome	2.4e-07	2.47e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6ST—epilepsy syndrome	2.39e-07	2.46e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOE—epilepsy syndrome	2.38e-07	2.45e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—epilepsy syndrome	2.37e-07	2.44e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HMOX1—epilepsy syndrome	2.35e-07	2.41e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—epilepsy syndrome	2.35e-07	2.41e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—epilepsy syndrome	2.34e-07	2.4e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—epilepsy syndrome	2.33e-07	2.39e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAT—epilepsy syndrome	2.32e-07	2.38e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RELA—epilepsy syndrome	2.31e-07	2.38e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—epilepsy syndrome	2.31e-07	2.37e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—SRC—epilepsy syndrome	2.27e-07	2.34e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MTOR—epilepsy syndrome	2.27e-07	2.33e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—epilepsy syndrome	2.23e-07	2.3e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—epilepsy syndrome	2.23e-07	2.29e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	2.22e-07	2.29e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—POMC—epilepsy syndrome	2.19e-07	2.25e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF2—epilepsy syndrome	2.18e-07	2.24e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	2.17e-07	2.23e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—JUN—epilepsy syndrome	2.17e-07	2.23e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	2.15e-07	2.22e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCL2—epilepsy syndrome	2.14e-07	2.2e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—epilepsy syndrome	2.13e-07	2.19e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—epilepsy syndrome	2.11e-07	2.17e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—epilepsy syndrome	2.11e-07	2.17e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GPX1—epilepsy syndrome	2.09e-07	2.15e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—epilepsy syndrome	2.09e-07	2.15e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—epilepsy syndrome	2.09e-07	2.15e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—epilepsy syndrome	2.06e-07	2.12e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—POMC—epilepsy syndrome	2.05e-07	2.11e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—JUN—epilepsy syndrome	2.03e-07	2.08e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RELA—epilepsy syndrome	2.03e-07	2.08e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MTOR—epilepsy syndrome	1.99e-07	2.04e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—epilepsy syndrome	1.97e-07	2.03e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—epilepsy syndrome	1.97e-07	2.03e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	1.94e-07	2e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—SRC—epilepsy syndrome	1.94e-07	2e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF2—epilepsy syndrome	1.93e-07	1.99e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—epilepsy syndrome	1.91e-07	1.97e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—epilepsy syndrome	1.91e-07	1.97e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—epilepsy syndrome	1.89e-07	1.95e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—ALB—epilepsy syndrome	1.87e-07	1.92e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—epilepsy syndrome	1.87e-07	1.92e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—epilepsy syndrome	1.86e-07	1.91e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	1.85e-07	1.9e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	1.84e-07	1.9e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AGT—epilepsy syndrome	1.84e-07	1.89e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—epilepsy syndrome	1.83e-07	1.88e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—SRC—epilepsy syndrome	1.82e-07	1.87e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOE—epilepsy syndrome	1.8e-07	1.85e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RELA—epilepsy syndrome	1.79e-07	1.84e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JUN—epilepsy syndrome	1.78e-07	1.83e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—epilepsy syndrome	1.77e-07	1.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MTOR—epilepsy syndrome	1.76e-07	1.81e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	1.76e-07	1.81e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—epilepsy syndrome	1.75e-07	1.8e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	1.74e-07	1.79e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TH—epilepsy syndrome	1.73e-07	1.78e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—epilepsy syndrome	1.73e-07	1.78e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—epilepsy syndrome	1.64e-07	1.69e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—epilepsy syndrome	1.63e-07	1.68e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—epilepsy syndrome	1.62e-07	1.66e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—epilepsy syndrome	1.62e-07	1.66e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—epilepsy syndrome	1.61e-07	1.66e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SRC—epilepsy syndrome	1.59e-07	1.64e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JUN—epilepsy syndrome	1.57e-07	1.62e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—epilepsy syndrome	1.55e-07	1.59e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—POMC—epilepsy syndrome	1.55e-07	1.59e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—epilepsy syndrome	1.54e-07	1.58e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—epilepsy syndrome	1.53e-07	1.57e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—epilepsy syndrome	1.53e-07	1.57e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—epilepsy syndrome	1.49e-07	1.53e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	1.45e-07	1.49e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAT—epilepsy syndrome	1.43e-07	1.47e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—epilepsy syndrome	1.41e-07	1.45e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—ALB—epilepsy syndrome	1.41e-07	1.45e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	1.39e-07	1.43e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—epilepsy syndrome	1.37e-07	1.41e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—epilepsy syndrome	1.35e-07	1.39e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	1.29e-07	1.33e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—epilepsy syndrome	1.25e-07	1.29e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—epilepsy syndrome	1.23e-07	1.27e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—epilepsy syndrome	1.21e-07	1.24e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AGT—epilepsy syndrome	1.13e-07	1.16e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—epilepsy syndrome	1.13e-07	1.16e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOE—epilepsy syndrome	1.11e-07	1.14e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—epilepsy syndrome	9.89e-08	1.02e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—POMC—epilepsy syndrome	9.52e-08	9.79e-07	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—epilepsy syndrome	8.76e-08	9.01e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—ALB—epilepsy syndrome	8.68e-08	8.93e-07	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—epilepsy syndrome	8.21e-08	8.45e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	7.6e-08	7.81e-07	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—epilepsy syndrome	6.2e-08	6.37e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	3.82e-08	3.93e-07	CbGpPWpGaD
